Introduction
Peripheral arterial disease (PAD) is a systemic disease with multiple atherosclerotic risk factors, and cardiovascular disease is the predominant cause of morbidity and mortality. 1, 2 An increased risk of cardiovascular events is related to severity of disease in the legs. 2 Patients with critical limb ischaemia (CLI) experience 20% mortality in the first year after presentation, 1 whereas those with intermittent claudication (IC) have more favourable survival and fate of the leg. 1, 3 However, available guidelines include different information on the fate of the leg. 1, 4, 5 In the ACC/AHA Guidelines for Management of Patients with PAD, the incidence of IC that progresses to CLI is 1-2% per 5 years; 4 but in the Inter-Society Consensus for Management of PAD (TASC-II), this rate is 5-10% per 5 years; 1 and in recent guidelines from the Society for Vascular Surgery, the rate is 1-3% per 5 years. 5 These three guidelines were developed from the same review by Hirsch et al., 4 but the progression rate in Hirsch et al. is based on a previous review by Weitz et al., 6 which includes data reported before 1988. 7, 8 Several studies have examined clinical outcomes of patients with IC, 9, 10 but these studies included patients with histories of endovascular treatment (EVT), bypass grafts, and amputation. Thus, the contemporary outcomes of de novo patients with IC have not been defined clearly. Moreover, the incidence of IC progression to CLI and the associated factors are unclear in de novo patients with PAD in recent long-term follow-up data. Therefore, the purpose of this study was to examine long-term life expectancy and fate of the leg, including the rate of progression of IC to CLI, in patients with de novo IC.
Methods Patients
Patients with de novo IC in the Cardiovascular Hospital of Central Japan (Kitakanto Cardiovascular Hospital) from January 1990 to December 2014 were included in a single-centre prospective cohort study. All patients had an ankle brachial pressure index (ABI) <0.90 at their first visit, with symptoms categorized as Fontaine class II and Rutherford stages 1-3. 11, 12 Patients with histories of limb EVT, bypass grafts, or amputation were excluded from the study. Written informed consent to participate in the study was obtained from all patients and the protocol was approved by our institutional ethical committee before initiation of the study.
Clinical and laboratory analysis
Clinical data were obtained by a thorough review of primary data, including age, ABI, body mass index (BMI), smoking history, diabetes, and hypertension. Coronary artery disease (CAD) was considered to be present if the patient had a history of this disease or showed a positive sign in stress/rest myocardial perfusion scintigraphy or coronary angiography. Cerebrovascular disease was considered positive if the patient had a history of this condition or if lesions due to cerebral infarction were found in brain computed tomography. Blood was collected during fasting to determine creatinine, albumin, total cholesterol, low-density lipoprotein (LDL) cholesterol, high-density lipoprotein (HDL) cholesterol, triglyceride, glucose, Creactive protein (CRP), and D-dimer levels.
Drug administration and treatments
All patients initially received exercise rehabilitation and medication for more than 3 months, and took one or more antiplatelet agents. Oral aspirin, ticlopidine, or clopidogrel was continued and an oral drug for treatment of IC (cilostazol, beraprost, or sarpogrelate) was added to exercise therapy. Patients with side effects received only one agent. Revascularization was performed in patients with IC whose symptoms were not improved or deteriorated after exercise/ medicine treatment.
Drugs for other conditions were added according to need. Oral drugs administered for more than 3 months or those administered within 3 months before death were classified as drug treatment. The effects of drug treatment were explained to the patients and we made efforts to ensure that patients continued with the prescribed drugs during visits to the outpatient department or at foot care lectures. Patients were classified into three groups based on treatment: exercise/medicine treatment, EVT, and bypass surgery. Those who received two or more kinds of treatment were included in the most invasive treatment group.
Data analysis and endpoints
Patients were followed up at 1, 3, and 6 months after the treatment and then evaluated at 4-or 6-month intervals at office visits. Vital signs and status of medications were assessed using hospital records and written questionnaires for quality of life completed at the Foot Care Club in our hospital or in response to an invitation letter. 3, 13 Through this club, we organized educational meetings to provide lectures on exercise programmes in our hospital, foot care, and new medical trends. An invitation to the meeting and a questionnaire were sent to each patient one time a year. The endpoints were overall survival (OS), freedom from major adverse cardiovascular events (MACE: all-cause death, non-fatal myocardial infarction, stroke, or transient ischaemic attack), 9 and freedom from major adverse cardiovascular and limb events (MACLE: MACE, any repeat revascularization for limb, and major amputation). Myocardial infarction was defined as described previously, 13, 14 and major amputation was defined as above-the-ankle amputation. Revascularization was performed in cases with worsening claudication and progression or restenosis of the lesion. Restenosis during follow-up was defined as a decrease in ABI of > _0.1 and > _50% stenosis on angiography or duplex ultrasonography.
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Statistical analysis Individual differences were considered to be significant at P < 0.05.
Results

Patient characteristics and causes of death
Follow-up was possible for 1107 of the 1153 subjects. The mean age of the 1107 patients was 71.4 ± 9.4 years old (range 38-97 years old). The median and mean follow-up periods were 64 (34-111) and 76.9 ± 60.6 months. The baseline characteristics and comorbidities of the patients are shown in Table 1 . All 1107 patients initially received exercise rehabilitation and medication. A flow diagram outlining the treatments and 5-year outcomes is shown in Figure 1 . Of 418 patients (37.8%) who continued exercise/ medicine treatment in the second stage, 10 (0.9%) had worsened claudication and underwent revascularization by EVT (n = 8) and bypass (n = 2) in the follow-up period. Of 531 patients (48.0%) treated with EVT, 14 (1.3%) had worsened claudication and underwent bypass surgery in the follow-up period. Therefore, in total, 408 patients (36.9%) were treated with exercise/medicine treatment alone, and revascularization was performed in 699 patients (63.1%) whose symptoms were not improved or deteriorated after exercise/ medicine treatment. Among all patients, 525 (47.4%) underwent EVT and 174 (15.7%) received bypass surgery ( Figure 1 ). Repeat percutaneous or surgical revascularization was performed in 223 (31.9%) of the 699 patients who underwent revascularization.
There were 478 deaths (43.2%) during follow-up due to cardiac or major vascular disease (n = 180, 37.7%), cerebrovascular disease (n = 78, 16.3%), malignancy (n = 107, 22.4%), pneumonia (n = 66, 13.8%), and other causes (n = 47, 9.8%). The prevalence of cardiovascular related deaths among those who died was 54.0% (n = 258). Among deaths due to cardiac or major vascular disease, 107 patients (41.5%) died due to acute myocardial infarction. The cumulative 5-, 10-, 15-, and 20-year rates for OS in all patients were 73.3, 47.8, 28.1, and 14.9%; those for freedom from MACE were 63.1, 35.6, 18.5, and 5.7%; and those for freedom from MACLE were 53.7, 28.5, 12.7, and 3.4%, respectively ( Figure 2 ).
Cox univariate and multivariable analysis of all-cause mortality
The results of Cox univariate analysis of potential risk factors and HRs for all-cause mortality are shown in Table 2 . Age, ABI, BMI, Rutherford classification, diabetes, cerebral infarction, haemodialysis, eGFR, albumin, D-dimer, and CRP were found to be significant factors associated with all-cause mortality. Treatment with a statin or aspirin was associated with improved mortality. Revascularization, including EVT, was significantly associated with improved mortality compared with exercise/medicine treatment.
In Cox multivariable analysis, age, BMI, diabetes, haemodialysis, CRP level, and statin use were significantly related to all-cause mortality. There was no significant difference in all-cause mortality between exercise/medicine treatment alone and revascularization (Table 2) .
Cox univariate and multivariable analysis of MACE and MACLE
The results of Cox univariate analysis for MACE are shown in Table  3 . Age, ABI, BMI, Rutherford classification, quinquennial survey, diabetes, CAD, cerebral infarction, haemodialysis, eGFR, albumin, D-dimer, and CRP were significantly associated with MACE. Statins improved MACE, and revascularization including EVT was also associated with improved MACE. In multivariable analysis, age, Rutherford classification, diabetes, CAD, haemodialysis, lower albumin, and higher CRP were independent factors associated with MACE (Table 3) . Statins improved MACE, but revascularization did not have this effect.
The results of Cox univariate analysis for MACLE are shown in Table 4 . Age, ABI, BMI, Rutherford classification, quinquennial survey, diabetes, CAD, cerebral infarction, haemodialysis, eGFR, and CRP were significantly associated with MACLE. Statins improved MACLE, but femoropopliteal EVT or surgical revascularization increased MACLE. In multivariable analysis, age, lower ABI, diabetes, CAD, haemodialysis, and higher CPR remained as independent factors associated with MACLE. Statins improved MACLE, but femoropopliteal revascularization increased MACLE.
Fate of the leg in patients with IC
Regarding limb morbidity, 881 patients (79.6%) had no deterioration of symptoms of IC (Figure 1 ). Worsening claudication was noted in 211 patients (19.1, 14 .8% per 5 years), and 15 (1.4%) worsened to CLI, giving a incidence of CLI that developed from IC of 1.1% per 5 years. Of the 15 patients with CLI, 13 had diabetes, 11 received haemodialysis, 7 had a history of cerebral infarction, and 6 received revascularization for a femoropopliteal (TASC-II Type-D) lesion by bypass surgery with an artificial graft (n = 3) and EVT with a stent (n = 3). 1 The cause of CLI was distal emboli or occlusion of belowthe-knee arteries caused by the artificial bypass graft or stent. Major and minor amputations were performed in 3 (0.27, 0.21% per 5 years) and 8 (0.72, 0.56% per 5 years) patients, respectively. In Cox univariate analysis, ABI, diabetes, cerebral infarction, haemodialysis, eGFR, and b-blocker use were significantly associated with progression of IC to CLI (Table 5 ). Aortoiliac revascularization reduced the risk of CLI, but femoropopliteal revascularization increased this risk. In Cox multivariable analysis, diabetes and haemodialysis were independent risk factors for CLI, and a history of cerebral infarction and femoropopliteal revascularization had a tendency to increase the risk of CLI.
Factors predicting revascularization and survey of statin use
The Rutherford classification was significantly more severe in patients who underwent revascularization compared with exercise/medicine treatment alone (P < 0.001), and in patients who received bypass surgery compared with EVT (P < 0.001). The results of Cox univariate and multivariable analyses for factors predicting revascularization are shown in Table 6 . Age, male, ABI, Rutherford classification, and smoking were significantly associated with revascularization. In multivariable analysis, younger age, severe Rutherford classification, and smoking remained as independent factors associated with revascularization.
A survey of prevalence of statin use divided into five 5-year periods ( Figure 3) showed a significant increase in usage with time (P < 0.001).
Discussion
All-cause mortality and MACE
This is the first report of 20-year life expectancy and fate of the leg in de novo patients with IC. Cardiovascular disease was a major cause of mortality, accounting for 54% of deaths. Mortality was strongly correlated with diabetes, and lower ABI also increased MACE in patients with IC. In patients with Type 2 diabetes, a lower ABI is related to a higher 5-year risk of a cardiovascular event. 16 These consistent results suggest that patients with diabetes and severe PAD have severe systemic atherosclerosis that is responsible for mortality and MACE. Haemodialysis was also found to be an independent risk factor for mortality. Several studies have suggested that chronic kidney disease is a prognostic indicator of cardiovascular disease [17] [18] [19] and cardiovascular mortality is 10-30 times higher in patients treated by haemodialysis than in the general population, after stratification for sex, race, and presence of diabetes. 17 The CRP is a useful inflammatory marker for predicting future cardiovascular events in patients with CAD, 20 and elevated CRP is associated with limb amputation and all-cause mortality after EVT in haemodialysis patients with PAD. 21 We have reported that low BMI is an independent predictor for all-cause mortality. 3 The mortality rates for different levels of BMI follow a J-shaped curve, with cardiovascular mortality showing a tendency for a bimodal distribution with two peaks in the lower and higher BMI strata.
In this study, the prevalence of statin use markedly increased with time, following guidelines of the era, and statins improved all-cause mortality and freedom from MACE. Statins reduce cardiovascular events 22 and have an antiatherogenic effect on coronary atherosclerosis, as well as a direct association with reduction of MACE. 23 Statin therapy is also effective for reducing all-cause mortality and MACE in symptomatic and asymptomatic patients with PAD, as detected by ABI measurement.
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MACLE and fate of IC
The incidence of CLI that developed from IC was only 1.1% per 5 years and the major amputation rate was 0.21% per 5 years. These results show that the rate of progression of IC to CLI is at the minimal reported level in published guidelines. 4, 5 As described above, diabetes and haemodialysis were found to be independent risk factors for CLI development from IC, but 80% of patients did not have deterioration of IC symptoms. This symptomatic stabilization may be due to the treatment of ischaemic arteries, development of collaterals, or metabolic adaptation of ischaemic muscle. 1, 26 A history of cerebral infarction and femoropopliteal revascularization had a tendency to increase the risk of IC progression to CLI. We have shown that cerebral infarction is an independent risk factor for progression of Fontaine stages in PAD, along with age, diabetes, and female gender. 27 Decreased physical capacity, sensory disturbance of wounds, and systemic atherosclerosis may also contribute to the risk. 1, 27 In this study, statins improved MACLE, and statin use is associated with an 18% lower rate of adverse limb outcomes in patients with PAD in the REACH registry. 10 These findings suggest that statins reduce the risk of mortality and MACE, and have a favourable effect on limb prognosis in patients with IC. In multivariable analysis, younger age, severe Rutherford classification, and smoking were independent factors associated with revascularization. Smoking is a major contributor to development of PAD. Even with some medications, most patients with PAD who smoke have low rates of successful smoking cessation during follow-up and show deterioration of symptoms of PAD, especially in IC. 28 Our results support previous findings that patients with PAD who smoke require early revascularization. There were no significant differences between the effects of exercise/medicine treatment and revascularization on all-cause mortality and MACE, but femoropopliteal revascularization increased MACLE and had a tendency to increase the risk of CLI. Aortoiliac revascularization has favourable long-term patency. 1, 5, 13 However, the success of surgical bypass for IC also depends on technical and anatomic factors, and randomized data regarding choice of conduit for femoropopliteal bypass demonstrate superior patency for saphenous vein grafts, compared with PTFE bypass surgery. 5, 29 Long-term patency of EVT in femoropopliteal lesions is improved with use of new devices, 26, 30 , but surgical revascularization with a saphenous vein graft is still the gold standard for a femoropopliteal long lesion. 
Study limitations
The limitations of the study are as follows. First, the sample sizes were relatively small and the study was performed at a single facility. Second, the prescription rate of statins was relatively low because this rate has increased over the time of the follow-up period. 10 Third, the serum level of high-sensitivity CRP is also an independent risk factor for cardiovascular disease and restenosis, 21 but only the serum level of non-high-sensitivity CRP was measured in cases before 2004. Fourth, walking rehabilitation modulates cardiovascular mortality, 32 and changes of lifestyle during follow-up were not accounted for in the study. Fifth, we could not analyse the effects of supervised exercise and changes over time in our hospital programme. These issues require examination in further studies of life expectancy and fate of the leg in patients with IC.
Conclusion
The incidence of CLI that developed from IC was 1.1% per 5 years and the major amputation rate was 0.21% per 5 years. Diabetes and haemodialysis were risk factors for all-cause mortality, MACE, MACLE, and progression of IC to CLI. Statins improved mortality, MACE, and MACLE, but revascularization did not improve mortality and MACE, and femoropopliteal revascularization reduced freedom from MACLE, compared with exercise rehabilitation and medication. Revascularization with a stent or artificial graft has a risk of CLI developing from IC in a long femoropopliteal lesion.
